QualityStocks would like to highlight
Nutra Pharma Corp. (
OTCQB: NPHC), a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma’s intellectual property is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.
In the company’s news,
Nutra Pharma Corp. (OTCQB: NPHC) is introducing new healthcare solutions to the globe. Through ReceptoPharm, a subsidiary, Nutra Pharma is discovering, researching and developing biopharmaceutical products to prevent and/or treat multiple sclerosis (MS), HIV/AIDS, adrenomyeloneuropathy (ADM), herpes, rheumatoid arthritis and pain.
Drug Discovery & Development
Nutra Pharma is in the business of acquiring, licensing and commercializing pharmaceutical products and technologies, along with homeopathic and ethical drugs for managing pain and neurological disorders, autoimmune and infectious diseases and cancer.
The company has several pipeline products both in the market and under research and development. Within the over-the-counter pain management market, Nutra Pharma is already marketing:
Nyloxin and Nyloxin Extra Strength, homeopathic drugs used to alleviate moderate to severe chronic pain; and
Pet Pain-Away, a homeopathic, non-addictive, non-narcotic pain reliever aimed at treating moderate to severe chronic pain in companion animals.
Nutra Pharma also has more than a few novel therapies in various stages of development, including:
Nyloxin Military Strength, a pain relieving drug intended for sale to the U.S. Military and Veteran’s Administration;
RPI-MN, a drug designed to treat viral diseases, such as HIV/AIDS and herpes;
RPI-78, which is geared toward managing pain and arthritis;
RPI-70, another pain reliever;
Equine Nyloxin, a topical therapy for horses; and
RPI-78M, which is designed to treat neurological diseases and autoimmune diseases, including MS, ADM and rheumatoid arthritis.
Through RPI-78M, Nutra Pharma reached new heights this year. In September, the U.S. Food and Drug Administration granted RPI-78M “orphan drug status” for the treatment of multiple sclerosis in children – a major milestone for the company. Not only is juvenile MS an important disease area, but it is one that is not being addressed by other drugs currently on the market. This creates a significant market opportunity for Nutra Pharma, as does the designation of RPI-78M as an orphan drug. With that label, Nutra Pharma has a 7-year period of market exclusivity in the U.S. once the drug is approved, and, based on its pre-clinical and open-label studies, the company feels quite strongly that it has the ability to successfully pass through this approval process.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
